Opinions on the reclassification of pulmonary adenocarcinoma in situ in the fifth edition of WHO classification of thoracic tumours
- VernacularTitle:第五版胸部肿瘤 WHO 分类中肺原位腺癌分类更改的解读
- Author:
Rusi ZHANG
1
;
Meifang ZHANG
2
;
Shugeng GAO
3
,
4
;
Gening JIANG
5
;
Qun WANG
6
;
Xiuyi ZHI
7
;
Lanjun ZHANG
1
Author Information
1. Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, P.R.China
2. Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, P.R.China
3. Department of Thoracic Surgical Oncology, Cancer Institute &
4. Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Center, Beijing, 100730, P.R.China
5. Department of Thoracic Surgery, Shanghai Pulmonary Hospital Tongji University, Shanghai, 200433, P.R.China
6. Department of Thoracic Surgery, Fudan University Affiliated Zhongshan Hospital, Shanghai, 200032, P.R.China
7. Department of Thoracic Surgery, Xuanwu Hospital of Capital Medical University, Beijing, 100053, P.R.China
- Publication Type:Journal Article
- Keywords:
WHO classification of thoracic tumours;
adenocarcinoma in situ;
lung cancer screening;
pulmonary nodule
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(09):1012-1015
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary adenocarcinoma in situ is reclassified as precursor glandular lesions in the fifth edition of WHO classification of thoracic tumours, causing widespread attention and heated debate among domestic thoracic oncologists, radiologists, pathologists and surgeons. We would like to comment on the topic and make a few suggestions on the management of pulmonary nodule during lung cancer screening. We are open to all suggestion and welcome debates.
